All In Biotech

Drug Trial Radar · NCT04641442

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blind, Placebo-controlled Design to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

17

Actual

Start

Dec 18, 2020

Primary completion

Oct 14, 2025

Study completion Nov 23, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.

Conditions

  • NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Interventions

  • MAS825Biological

    Experimental drug

  • PlaceboBiological

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Occurrence of disease flare in patients with MAS825 treated patients compared with placebo during Period 2 assessed by Physician's Global Assessment and inflammatory markersTime frame: Period 2 (during the randomized, placebo-controlled period of up to 6 months)

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Children´s Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Texas Children´s Hospital

    Houston, Texas

  • Seattle Children´s Hospital

    Seattle, Washington

  • Ustav Imunologie 2 LF UK a FN Motol

    Prague, Czechia

  • Centrum detske revmatologie a autoinflamatornich onemocneni

    Prague, CZ, Czechia

  • Novartis Investigative Site

    Paris, France

  • Bambino Gesu Hospital

    Roma, RM, Italy

  • Novartis Investigative Site

    Chiba, Japan

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.